About Nutron Pharmaceuticals Private Limited
Data last updated: 22 December 2025
Nutron Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It specialises in chemical distribution and retail, a part of the broader chemicals and materials sector. Incorporated on 12 October 1990, the company has been in operation for over 36 years.
Registered with ROC Mumbai under CIN U24230MH1990PTC058515.
Capital: an authorised share capital of ₹25 Lakh and a paid-up capital of ₹4.83 Lakh. It is led by directors including Ritesh Ramesh Shah and Praful Ramesh Shah.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 401 Earth Sampann Bldg 198/200 Khetwadi Main Road 4Th Floor, Mumbai, Maharashtra, India – 400004.
As per the financials filed for FY 2025, the company reported a revenue of ₹51.48 Cr, a growth of 1% compared to the previous year.
As per MCA filings, the company has open charges of ₹15 Cr and satisfied charges of ₹26.94 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nutron.lookchem.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address401 Earth Sampann Bldg 198/200 Khetwadi Main Road 4Th Floor, Mumbai, Maharashtra, India – 400004
-
IndustryChemicals and Materials, Chemical Distribution & Retail
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Nutron Pharmaceuticals Private Limited
Nutron Pharmaceuticals Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Nutron Pharmaceuticals Private Limited
Nutron Pharmaceuticals Private Limited is audited by V. C. SHAH & CO. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| V. C. SHAH & CO. | blur-value | blur-value | blur-value |
Board of Directors of Nutron Pharmaceuticals Private Limited
Nutron Pharmaceuticals Private Limited is currently managed by 7 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Ritesh Ramesh Shah
Also directs:
Mehal Enterprise Llp, Terrapolis Buildcon Private Limited, New Dholera Shipping & Trading Co Limited and 1 more
|
Director | 18 Oct 2012 | 13 Years 8 Months | Current |
| Praful Ramesh Shah | Director | 18 Oct 2012 | 13 Years 8 Months | Current |
| Popatlal Hanjarimal Shah | Director | 12 Oct 1990 | 35 Years 8 Months | Current |
|
Jayesh Popatlal Shah
Also directs:
Mehal Enterprise Llp, Terrapolis Buildcon Private Limited
|
Director | 15 Mar 1999 | 27 Years 3 Months | Current |
|
Ramesh Hanjarimal Shah
Also directs:
Mehal Enterprise Llp
|
Director | 12 Oct 1990 | 35 Years 8 Months | Current |
|
Manish Bhuralal Shah
Also directs:
Mehal Enterprise Llp, Terrapolis Buildcon Private Limited
|
Director | 03 Apr 1995 | 31 Years 3 Months | Current |
Financials of Nutron Pharmaceuticals Private Limited FY 2025 filings available
Nutron Pharmaceuticals Private Limited reported revenue of ₹51.48 Cr (up 1% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Nutron Pharmaceuticals Private Limited
As of FY 2023, Nutron Pharmaceuticals Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Nutron Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jan 2021 | Others | ₹15 Cr | Open |
| 15 Feb 2008 | Citi Bank N.A. | ₹22.5 Cr | Satisfied |
| 05 Mar 2007 | Citibank N.A. | ₹2.5 Cr | Satisfied |
| 17 Sep 2003 | The Sangli Bank Limited | ₹1.5 Cr | Satisfied |
| 28 Jul 1998 | Bank of Madura Ltf | ₹9.33 Lakh | Satisfied |
Total charge records: 7 View all charges
Employees and EPFO Compliance at Nutron Pharmaceuticals Private Limited
View historical data on people associated with Nutron Pharmaceuticals Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Nutron Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Nutron Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Nutron Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Nutron Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Nutron Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Nutron Pharmaceuticals Private Limited
MSME Payment Delays by Nutron Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Nutron Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Nutron Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Nutron Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Nutron Pharmaceuticals Private Limited
MCA Filings & Documents of Nutron Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Nutron Pharmaceuticals Private Limited
Frequently Asked Questions about Nutron Pharmaceuticals Private Limited
Nutron Pharmaceuticals Private Limited is an active private limited company in the chemicals and materials sector based in Mumbai, Maharashtra, India. It was incorporated on 12 October 1990 (36+ years old) and is registered under CIN U24230MH1990PTC058515.
Nutron Pharmaceuticals Private Limited reported revenue of ₹51.48 Cr for FY 2025 (up 1.00% YoY).
The current directors of Nutron Pharmaceuticals Private Limited are:
The primary industry of Nutron Pharmaceuticals Private Limited is chemicals and materials. The company specifically operates in chemical distribution and retail. The company is currently active in this sector.
Nutron Pharmaceuticals Private Limited can be reached at the registered office: 401 Earth Sampann Bldg 198200 Khetwadi Main Road 4Th Floor, Mumbai, Maharashtra, India – 400004, or through the website nutron.lookchem.com.
The authorised capital is ₹25 Lakh, and the paid-up capital is ₹4.83 Lakh.